Another study confirmed that targeting CXCR4 can inhibit the growth of pancreatic cancer cells and increase the sensitivity of pancreatic cancer cells to gemcitabine (Khan et al., 2020). The gene discussed is CXCR4; the disease is pancreatic neoplasm.